Ovarian Cancer CER-T

About Anixa Biosciences

Anixa Biosciences is a clinical-stage biotech focused on transforming oncology through its innovative 'retired protein' antigen platform, which aims to deliver tumor-specific immunotherapies with improved safety profiles. The company's two core technologies are a novel CER-T (Chimeric Endocrine Receptor T-cell) therapy for ovarian cancer and a vaccine platform targeting triple-negative breast cancer (TNBC) and ovarian cancer for both treatment and prevention. Recent milestones include advancing its breast cancer vaccine toward Phase 2 and presenting early clinical data for its ovarian cancer CAR-T therapy. Anixa's strategy targets significant unmet needs in solid tumors by aiming to overcome the on-target, off-tumor toxicity that has limited broader application of current immunotherapies.

Therapeutic Areas

Other Recurrent Ovarian Cancer Drugs